Investigation of Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (OASM) Accused of Improper Related-Party Transactions

According to the complaint, for alleged violations of the Securities Exchange Act of 1934 between October 23, 2015 and July 9, 2019, Oasmia filed its preliminary prospectus with the SEC, which stated that it had no off-balance sheets or related-party transactions that could materially affect Oasmia’s financial condition or operations. Included within the related-party transactions were Alceco International and Ardenia Investment LTD, two companies that were controlled by Oasmia’s CEO, Julian Aleksov, and his former father-in-law. Oasmia continued to affirm these materially false and misleading statements in its later filings with the SEC; however, in reality, Oasmia was engaged in improper related-party transactions with Alceco and Ardenia, with millions of Swedish kronor unaccounted for in Oasmia’s books. Then, on June 28, 2019, Oasmia issued a press release stating that it was reporting suspicious transactions between Oasmia, Alceco, and Ardenia found in its tax audit to the Swedish Economic Crime Authority. Then, on July 9, 2019, Oasmia announced that it terminated Julian Aleksov for his involvement with the suspicious transactions. As a result, Oasmia’s stock has fallen almost 35% and currently trades at $1.70.

Oasmia Pharmaceuticals AB (OASM) Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can send us a message via the Shareholder Information below.

Send us a message for more information.

Protect your investments.

Sign up for free investment monitoring.

Stock Watch members receive free investment monitoring and notifications.  

Leave your details to get started